STAT6 phosphorylation upregulates microRNA‑155 expression and subsequently enhances the pathogenesis of chronic lymphocytic leukemia

Chen,Na; Feng,Lili; Lu,Kang; Li,Peipei; Lv,Xiao; Wang,Xin

doi:10.3892/ol.2019.10294

STAT6 phosphorylation upregulates microRNA‑155 expression and subsequently enhances the pathogenesis of chronic lymphocytic leukemia

Authors:
- Na Chen
- Lili Feng
- Kang Lu
- Peipei Li
- Xiao Lv
- Xin Wang
View Affiliations

Affiliations: Department of Hematology, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China
Published online on: April 30, 2019 https://doi.org/10.3892/ol.2019.10294
Pages: 95-100

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chronic lymphocytic leukemia (CLL), a clonal expansion of CD5+ B cells, is the most common form of adult leukemia; however, the molecular mechanisms underlying its pathogenesis remain undetermined. It has been previously suggested that numerous biological factors, including cytokines, may be involved in the proliferation of malignant cells. For example, interleukin (IL)‑4, IL‑2, interferon‑γ and tumor necrosis factor serve roles as inhibitors of cellular apoptosis; whereas IL‑5 and IL‑10 are inducers of cellular apoptosis. In the present study, the results demonstrated that the phosphorylation and activation of signal transducer and activator of transcription 6 (STAT6) was induced by IL‑4 in a time‑dependent manner. Notably, the expression level of microRNA (miR)‑155 was increased in MEC‑1 cells following treatment with IL‑4; however, this effect was attenuated following STAT6 knockdown via RNA interference. In addition, STAT6 knockdown promoted cell apoptosis, which was partly attenuated by treatment with IL‑4. Inhibition of miR‑155 expression significantly increased cell apoptosis despite the presence of IL‑4. The results of the present study suggested that treatment with IL‑4 enhanced the expression of miR‑155, which regulated CLL cell survival via the enhanced phosphorylation of STAT6.

View Figures

View References

1	Lu K and Wang X: Therapeutic advancement of chronic lymphocytic leukemia. J Hematol Oncol. 5:552012. View Article : Google Scholar : PubMed/NCBI
2	Bilous N, Abramenko I, Saenko V, Chumak A, Dyagil I, Martina Z and Kryachok I: Clinical relevance of TP53 polymorphic genetic variations in chronic lymphocytic leukemia. Leuk Res. 58:1–8. 2017. View Article : Google Scholar : PubMed/NCBI
3	Nasr R, Marçais A, Hermine O and Bazarbachi A: Overview of targeted therapies for adult T-cell leukemia/lymphoma. Methods Mol Biol. 1582:197–216. 2017. View Article : Google Scholar : PubMed/NCBI
4	Jin UH, Cheng Y, Zhou B and Safe S: Bardoxolone methyl and a related triterpenoid downregulate cMyc expression in leukemia cells. Mol Pharmacol. 91:438–450. 2017. View Article : Google Scholar : PubMed/NCBI
5	Quintanilla-Martinez L, Preffer F, Rubin D, Ferry JA and Harris NL: CD20+ T-cell lymphoma: Neoplastic transformation of a normal T-cell subset. Am J Clin Pathol. 102:483–489. 1994. View Article : Google Scholar : PubMed/NCBI
6	Moens L, Verbinnen B, Covens K, Wuyts G, Johnson M, Roalfe L, Goldblatt D, Meyts I and Bossuyt X: Anti-pneumococcal capsular polysaccharide antibody response and CD5 B lymphocyte subsets. Infect Immun. 83:2889–2896. 2015. View Article : Google Scholar : PubMed/NCBI
7	Balatti V, Tomasello L, Rassenti LZ, Veneziano D, Nigita G, Wang HY, Thorson JA, Kipps TJ, Pekarsky Y and Croce CM: miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients. Blood. 132:2179–2182. 2018. View Article : Google Scholar : PubMed/NCBI
8	Papageorgiou SG, Kontos CK, Diamantopoulos MA, Bouchla A, Glezou E, Bazani E, Pappa V and Scorilas A: MicroRNA-155-5p overexpression in peripheral blood mononuclear cells of chronic lymphocytic leukemia patients is a novel, independent molecular biomarker of poor prognosis. Dis Markers. 2017:20465452017. View Article : Google Scholar : PubMed/NCBI
9	Zitzer NC, Snyder K, Meng X, Taylor PA, Efebera YA, Devine SM, Blazar BR, Garzon R and Ranganathan P: MicroRNA-155 modulates acute graft-versus-host disease by impacting T cell expansion, migration, and effector function. J Immunol. 200:4170–4179. 2018. View Article : Google Scholar : PubMed/NCBI
10	Zhou B, Zhu H, Luo H, Gao S, Dai X, Li Y and Zuo X: MicroRNA-202-3p regulates scleroderma fibrosis by targeting matrix metalloproteinase 1. Biomed Pharmacother. 87:412–418. 2017. View Article : Google Scholar : PubMed/NCBI
11	Oscier D, Else M, Matutes E, Morilla R, Strefford JC and Catovsky D: The morphology of CLL revisited: The clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial. Br J Haematol. 174:767–775. 2016. View Article : Google Scholar : PubMed/NCBI
12	Kriston C, Bödör C, Szenthe K, Bánáti F, Bánkuti B, Csernus B, Reiniger L, Csomor J, Matolcsy A and Barna G: Low CD23 expression correlates with high CD38 expression and the presence of trisomy 12 in CLL. Hematol Oncol. 35:58–63. 2017. View Article : Google Scholar : PubMed/NCBI
13	Underbayev C, Kasar S, Ruezinsky W, Degheidy H, Schneider JS, Marti G, Bauer SR, Fraidenraich D, Lightfoote MM, Parashar V, et al: Role of mir-15a/16-1 in early B cell development in a mouse model of chronic lymphocytic leukemia. Oncotarget. 7:60986–60999. 2016. View Article : Google Scholar : PubMed/NCBI
14	Dong C, Ji M and Ji C: microRNAs and their potential target genes in leukemia pathogenesis. Cancer Biol Ther. 8:200–205. 2009. View Article : Google Scholar : PubMed/NCBI
15	Smolej L, Vroblova V, Motyckova M, Jankovicova K, Schmitzova D, Krejsek J and Maly J: Quantification of ZAP-70 expression in chronic lymphocytic leukemia: T/B-cell ratio of mean fluorescence intensity provides stronger prognostic value than percentage of positive cells. Neoplasma. 58:140–145. 2011. View Article : Google Scholar : PubMed/NCBI
16	Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, Nouraee N, Ikuo M, Ghosh AK, Lerner S, Rassenti LZ, et al: Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 122:1891–1899. 2013. View Article : Google Scholar : PubMed/NCBI
17	Yan C, Chen Y, Kong W, Fu L, Liu Y, Yao Q and Yuan Y: PVT1-derived miR-1207-5p promotes breast cancer cell growth by targeting STAT6. Cancer Sci. 108:868–876. 2017. View Article : Google Scholar : PubMed/NCBI
18	Chen N, Lu K, Li P, Lv X and Wang X: Overexpression of IL-9 induced by STAT6 activation promotes the pathogenesis of chronic lymphocytic leukemia. Int J Clin Exp Pathol. 7:2319–2323. 2014.PubMed/NCBI
19	Chen N, Lv X, Li P, Lu K and Wang X: Role of high expression of IL-9 in prognosis of CLL. Int J Clin Exp Pathol. 7:716–721. 2014.PubMed/NCBI
20	Kneitz C, Goller M, Seggewiss R, Yaman A, Serfling E and Tony HP: STAT6 and the regulation of CD23 expression in B-chronic lymphocytic leukemia. Leuk Res. 24:331–337. 2000. View Article : Google Scholar : PubMed/NCBI
21	Jeon JI, Ko SH, Kim YJ, Choi SM, Kang KK, Kim H, Yoon HJ and Kim JM: The flavone eupatilin inhibits eotaxin expression in an NF-κB-dependent and STAT6-independent manner. Scand J Immunol. 81:166–176. 2015. View Article : Google Scholar : PubMed/NCBI
22	Eigsti RL, Sudan B, Wilson ME and Graff JW: Regulation of activation-associated microRNA accumulation rates during monocyte-to-macrophage differentiation. J Biol Chem. 289:28433–28447. 2014. View Article : Google Scholar : PubMed/NCBI
23	Rückerl D, Jenkins SJ, Laqtom NN, Gallagher IJ, Sutherland TE, Duncan S, Buck AH and Allen JE: Induction of IL-4Rα-dependent microRNAs identifies PI3K/Akt signaling as essential for IL-4-driven murine macrophage proliferation in vivo. Blood. 120:2307–2316. 2012. View Article : Google Scholar : PubMed/NCBI
24	Gautherot I, Burdin N, Seguin D, Aujame L and Sodoyer R: Cloning of interleukin-4 delta2 splice variant (IL-4delta2) in chimpanzee and cynomolgus macaque: phylogenetic analysis of delta2 splice variant appearance, and implications for the study of IL-4-driven immune processes. Immunogenetics. 54:635–644. 2002. View Article : Google Scholar : PubMed/NCBI
25	Wei Y and Schober A: MicroRNA regulation of macrophages in human pathologies. Cell Mol Life Sci. 73:3473–3495. 2016. View Article : Google Scholar : PubMed/NCBI
26	Czimmerer Z, Varga T, Kiss M, Vázquez CO, Doan-Xuan QM, Rückerl D, Tattikota SG, Yan X, Nagy ZS, Daniel B, et al: The IL-4/STAT6 signaling axis establishes a conserved microRNA signature in human and mouse macrophages regulating cell survival via miR-342-3p. Genome Med. 8:632016. View Article : Google Scholar : PubMed/NCBI
27	Ying W, Tseng A, Chang RC, Morin A, Brehm T, Triff K, Nair V, Zhuang G, Song H, Kanameni S, et al: MicroRNA-223 is a crucial mediator of PPARγ-regulated alternative macrophage activation. J Clin Invest. 125:4149–4159. 2015. View Article : Google Scholar : PubMed/NCBI
28	Friedländer MR, Lizano E, Houben AJ, Bezdan D, Báñez-Coronel M, Kudla G, Mateu-Huertas E, Kagerbauer B, González J, Chen KC, et al: Evidence for the biogenesis of more than 1,000 novel human microRNAs. Genome Biol. 15:R572014. View Article : Google Scholar : PubMed/NCBI
29	Srivastava AK, Sablok G, Hackenberg M, Deshpande U and Suprasanna P: Thiourea priming enhances salt tolerance through co-ordinated regulation of microRNAs and hormones in Brassica juncea. Sci Rep. 7:454902017. View Article : Google Scholar : PubMed/NCBI
30	Pallasch CP, Patz M, Park YJ, Hagist S, Eggle D, Claus R, Debey-Pascher S, Schulz A, Frenzel LP, Claasen J, et al: miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood. 114:3255–3264. 2009. View Article : Google Scholar : PubMed/NCBI
31	Abroun S, Saki N, Ahmadvand M, Asghari F, Salari F and Rahim F: STATs: An old story, yet mesmerizing. Cell J. 17:395–411. 2015.PubMed/NCBI